HC Wainwright Forecasts Erasca’s Q1 Earnings (NASDAQ:ERAS)

Erasca, Inc. (NASDAQ:ERAS) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Erasca in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings of ($0.11) per share for the quarter. The consensus estimate for Erasca’s current full-year earnings is ($0.73) per share.

Erasca (NASDAQ:ERAS) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.11) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.11).

A number of other brokerages have also recently issued reports on ERAS. Bank of America reiterated an “underperform” rating and issued a $1.00 price target (down previously from $4.00) on shares of Erasca in a research note on Wednesday, September 3rd. Morgan Stanley reaffirmed an “equal weight” rating and issued a $2.00 target price (down from $4.00) on shares of Erasca in a report on Monday, August 18th. Stifel Nicolaus set a $6.00 price target on shares of Erasca in a report on Thursday, November 6th. Guggenheim boosted their price objective on shares of Erasca from $3.00 to $5.00 and gave the stock a “buy” rating in a report on Friday. Finally, Wall Street Zen raised Erasca from a “sell” rating to a “hold” rating in a research report on Sunday, September 21st. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $4.25.

Erasca Stock Up 5.3%

Shares of NASDAQ ERAS traded up $0.14 during trading on Friday, reaching $2.68. The company had a trading volume of 430,950 shares, compared to its average volume of 1,435,532. Erasca has a 12-month low of $1.01 and a 12-month high of $3.30. The business’s 50-day moving average is $2.16 and its 200 day moving average is $1.70. The stock has a market cap of $758.82 million, a PE ratio of -5.90 and a beta of 1.19.

Hedge Funds Weigh In On Erasca

Several hedge funds and other institutional investors have recently modified their holdings of ERAS. Captrust Financial Advisors grew its holdings in shares of Erasca by 13.6% in the second quarter. Captrust Financial Advisors now owns 54,111 shares of the company’s stock worth $69,000 after acquiring an additional 6,486 shares during the period. BNP Paribas Financial Markets boosted its position in Erasca by 58.0% in the second quarter. BNP Paribas Financial Markets now owns 21,579 shares of the company’s stock worth $27,000 after purchasing an additional 7,923 shares during the last quarter. New York State Common Retirement Fund boosted its position in Erasca by 39.1% in the second quarter. New York State Common Retirement Fund now owns 37,360 shares of the company’s stock worth $47,000 after purchasing an additional 10,501 shares during the last quarter. Sio Capital Management LLC grew its stake in shares of Erasca by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 1,369,748 shares of the company’s stock valued at $1,740,000 after purchasing an additional 13,562 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Erasca during the 3rd quarter valued at about $31,000. 67.78% of the stock is owned by institutional investors.

About Erasca

Erasca, Inc, a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma.